

Idaho Incubation Fund Program

Progress Report Form

Proposal No. IF15-002 (BSU 691A100419)
Name: Dr. Cheryl Jorcyk
Name of Institution: Boise State University
Project Title: Small Molecule Inhibitors for the Reduction of Cancer Metastasis
Reporting Period: July 1, 2014 to November 30, 2014

Information to be reported in your progress report is as follows (attach additional information as needed):

1. Summary of project accomplishments for the period just completed and plans for the coming reporting period:

Our lab has been developing functional assays. These assays can be used to determine if OSM-SMIs will block the functions produced by OSM acting on tumor cells in culture. We have developed a tumor cell proliferation/detachment assay that shows that OSM-SMI-8 inhibits OSM-induced prostate tumor cell proliferation and detachment.

Our collaborator, Dr. Don Warner, has been synthesizing OSM-SMI compounds. Currently, he has produced three carboxylic ester compounds that are ready for testing in the lab. He will continue with synthesis. We will be testing these new compounds in January 2015.

2. Summary of budget expenditures for the period just completed (include project burn rate):

Operating Expenses (Materials & Supplies): \$1,649.93

Burn Rate: > 3%

3. Numbers of faculty and student participation resulting from the funding, including internships:

Research participants include:

Two faculty (Drs. Cheryl Jorcyk and Don Warner)

One PhD student (Ken Tawara)

One technician (Daniel Hedeem)

Four undergraduate students

4. List patents, copyrights, plant variety protection certificates received or pending:

One patent application (#P10980US01) entitled “Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders” was submitted 9/5/14.

5. List technology licenses signed and start-up businesses created:

None

6. Status of private/industry partnerships (include enough information to judge level of engagement):

None

7. Any other pertinent information that will indicate to the council that the project is meeting satisfactory progress.

We have obtained IACUC (International Animal Care and Use Committee) approval to test OSM-SMIs in a mouse model of breast cancer.